TSTD2

Across TCGA pan-cancer cohorts, TSTD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSTD2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TSTD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSTD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, UCEC, and GBM are the cancer types where TSTD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.206	0.484	.005	45	view →
UCEC	OS	Median	All	1.000	0.925	.018	8	view →
GBM	DFS	Quartile	All	0.508	0.281	.026	4	view →
LSCC	DFS	Median	III,IV	0.472	0.810	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TSTD2–PDAC (DFS)

Open the PDAC breakdown →